Law360, New York (June 22, 2012, 7:12 PM ET) -- The U.S. Food and Drug Administration told Watson Pharmaceuticals Inc. and Swedish Orphan Biovitrum AB to stop publishing allegedly misleading advertisements for their anemia treatment and cancer-related mucositis drugs, respectively, according to letters made public Thursday.
In letters dated June 7, the FDA told Watson that a journal ad for its Nulecit anemia treatment makes unsubstantiated claims, while warning Sobi that its ads for Kepivance, a drug that helps people regenerate cells in the mouth and intestinal tract during cancer treatment, omit certain risk information while...
FDA Tells Watson, Swedish Drugmaker To Pull Misleading Ads
To view the full article, take a free trial now.
